Structural aspects of high affinity ligands for the α4β2 neuronal nicotinic receptor

Pharmaceutica Acta Helvetiae

Volumn 74, Issue 2-3, 2000, Pages 115-123

  Dart, Michael J ^a   Wasicak, James T ^a   Ryther, Keith B ^a   Schrimpf, Michael R ^a   Kim, Ki H ^a   Anderson, David J ^a   Sullivan, James P ^a   Meyer, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

c4 2; 2 azabicyclo 2.2.1 heptane; Epibatidine; Furo 2,3 b pyridine; Furo 2,3 c pyridine; Furo 3,2 b pyridine; Furo 3,2 c pyridine; Molecular modelling; Nicotine; Nicotinic acetylcholine receptor (nAChR); Pharmacophore; Pyridyl ether; Pyrrolizidine

Indexed keywords

2 AZABICYCLO[2.2.1]HEPTANE DERIVATIVE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; A 84543; A 98795; CYTISINE; EPIBATIDINE; FURO[2,3 B]PYRIDINE DERIVATIVE; LIGAND; NICOTINE; NICOTINIC RECEPTOR; PROTEIN SUBUNIT; PYRROLIZIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; BINDING AFFINITY; BINDING SITE; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; IN VITRO STUDY; LIGAND BINDING; NONHUMAN; PHARMACOPHORE; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; THEORY;

ANIMALS; BRAIN CHEMISTRY; LIGANDS; MODELS, MOLECULAR; RATS; RECEPTORS, NICOTINIC;

EID: 0034026472     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(99)00023-0     Document Type: Conference Paper

References (55)

1. Abreo M.A., Lin N.-H., Garvey D.S., Gunn D.E., Hettinger A.-M., Wasicak J.T., Pavlik P.A., Martin Y.C., Donnelly-Roberts D.L., Anderson D.J., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J. Med. Chem. 39:1996;817-825.
2. Alkondon M., Pereira E.F.R., Eisenberg H.M., Albuquerque E.X. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J. Neurosci. 19:1999;2693-2705.
3. Arneric S.P., Anderson D.J., Bannon A.W., Briggs C.A., Buccafusco J.J., Brioni J.D., Cannon J.B., Decker M.W., Donnelly-Roberts D., Gopalakrishnan M., Holladay M.W., Kyncl J., March K.C., Radek R.J., Rodrigues A.D., Sullivan J.P. Preclinical pharmacology of ABT-418: A prototypical cholinergic channel activator for the potential treatment of Alzheimer's disease. CNS Drug Rev. 1:1995;1-26.
4. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Porsolt R.D., Williams M., Arneric S.P. Broad-spectrum, nonopioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science (Washington, DC). 279:1998;77-81.
5. Barlocco D., Cignarella G., Tondi D., Vianello P., Villa S., Bartolini A., Ghelardini C., Galeotti N., Anderson D.J., Kuntzweiler T.A., Colombo D., Toma L. Mono- and disubstituted-3,8-diazabicyclo[3.2.1]octane derivatives as analgesics structurally related to epibatidine: synthesis, activity and modeling. J. Med. Chem. 41:1998;674-681.
6. Beers W.H., Reich E. Structure and activity of acetylcholine. Nature. 228:1970;917-922.
7. Bencherif M., Schmitt J.D., Bhatti B.S., Crooks P., Caldwell W.S., Lovette M.E., Fowler K., Reeves L., Lippiello P.M. The heterocyclic substituted pyridine derivative (±)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 284:1998;886-894.
8. Bitner R.S., Nikkel A.L., Curzon P., Arneric S.P., Bannon A.W., Decker M.W. Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. J. Neurosci. 18:1998;5426-5432.
9. Brioni J.D., Decker M.W., Sullivan J.P., Arneric S.P. The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv. Pharmacol. (San Diego). 37:1997;153-214.
10. Campillo, N., Antonio Paez, J., Alkorta, I., Goya, P., 1998. A theoretical study of epibatidine, J. Chem. Soc., Perkin Trans. 2, 2665-2670.
11. Czajkowski C., Karlin A. Structure of the nicotinic receptor acetylcholine-binding site. Identification of acidic residues in the δ subunit within 0.9 nm of the α subunit-binding site disulfide. J. Biol. Chem. 270:1995;3160-3164.
12. Dougherty D.A. Cation-π interactions in chemistry and biology: a new view of benzene, Phe, Tyr and Trp. Science (Washington, DC). 271:1996;163-168.
13. Dukat M., Damaj M.I., Glassco W., Dumas D., May E.L., Martin B.R., Glennon R.A. Epibatidine: a very high affinity nicotine-receptor ligand. Med. Chem. Res. 4:1994;131-139.
14. Dukat M., Dowd M., Damaj M.I., Martin B., El-Zahabi M.A., Glennon R.A. Synthesis, receptor binding and QSAR studies on 6-substituted nicotine derivatives as cholinergic ligands. Eur. J. Med. Chem. 34:1999;31-40.
15. Edelstein S.J., Changeux J.-P. Allosteric transitions of the acetylcholine receptor. Adv. Protein Chem. 51:1998;121-184.
16. Elliott R.E., Kopecka H., Gunn D.E., Lin N.-H., Garvey D.S., Ryther K.B., Holladay M.W., Anderson D.J., Campbell J.E., Sullivan J.P., Buckley M.J., Gunther K.L., O'Neill A.B., Decker M.W., Arneric S.P. 2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands. Bioorg. Med. Chem. Lett. 6:1996;2283-2288.
17. Elliott R.L., Ryther K.B., Anderson D.J., Piattoni-Kaplan M., Kuntzweiler T.A., Donnelly-Roberts D., Arneric S.P., Holladay M.W. Novel 2-(2′-furo[3,2-b]-pyridinyl) pyrrolidines: potent neuronal nicotinic acetylcholine receptor ligands. Bioorg. Med. Chem. Lett. 7:1997;2703-2708.
18. Elliott, R.L., Ryther, K.B., Holladay, M.W., Wasciak, J.T., Daanen, J.F., Lin, N.-H., Dart, M.J., He, Y., Li, Y., 1998. Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission. WO 9846609.
19. Garvey D.S., Wasicak J.T., Elliott R.L., Lebold S.A., Hettinger A.-M., Carrera G.M., Lin N.-H., He Y., Holladay M.W., Anderson D.J., Cadman E.D., Raszkiewicz J.L., Sullivan J.P., Arneric S.P. Ligands for brain cholinergic channel receptors: synthesis and in vitro characterization of novel isoxazoles and isothiazoles as bioisosteric replacements for the pyridine ring in nicotine. J. Med. Chem. 37:1994;4455-4463.
20. Glennon R.A., Dukat M. Nicotine receptor ligands. Med. Chem. Res. 6:1996;465-486.
21. Glennon, R.A., Dukat, M., 1999. Nicotinic cholinergic receptor pharmacophores. In: Arneric, S.P., Brioni, J.D. (Eds.), Neuronal Nicotinic Receptors. Wiley-Liss, New York, NY, 271-284.
22. Glennon R.A., Herndon J.L., Dukat M. Epibatidine-aided studies toward definition of a nicotine receptor pharmacophore. Med. Chem. Res. 4:1994;461-473.
23. 3H ]dopamine release from mouse striatal synaptosomes and response to chronic L-nicotine treatment J. Pharmacol. Exp. Ther. 282:1997;32-43.
24. Harel M., Schalk I., Ehret-Sabatier L., Bouet F., Goeldner M., Hirth C., Axelsen P.H., Silman I., Sussman J.L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 90:1993;9031-9035.
25. Hodgson, D.M., Maxwell, C.R., Matthews, I.R., 1998. An epoxide rearrangement. Radical rearrangement approach to 6-substituted 2-azabicyclo[2.2.1]-5-heptenes. Synthesis of an epibatidine analog. Synlett., 1349-1350.
26. Holladay M.W., Wasicak J.T., Lin N.-H., He Y., Ryther K.B., Bannon A.W., Buckley M.J., Kim D.J.B., Decker M.W., Anderson D.J., Campbell J.E., Kuntzweiler T.A., Donnelly-Roberts D.L., Piattoni-Kaplan M., Briggs C.A., Williams M., Arneric S.P. Identification and structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. 41:1998;407-412.
27. Kanne D.B., Abood L.G. Synthesis and biological characterization of pyridohomotropanes. Structure-activity relationships of conformationally restricted nicotinoids. J. Med. Chem. 31:1988;506-509.
28. Karlin A. Structure of nicotinic acetylcholine receptors. Curr. Opin. Neurobiol. 3:1993;299-309.
29. Kasyan A., Wagner C., Maier M.E. Regiochemistry of the reductive Heck coupling of 2-azabicyclo[2.2.1]hept-5-ene. Synthesis of epibatidine analogs. Tetrahedron. 54:1998;8047-8054.
30. Koren A.O., Horti A.G., Mukhin A.G., Guendisch D., Kimes A.S., Dannals R.F., London E.D. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors and molecular modeling. J. Med. Chem. 41:1998;3690-3698.
31. Lena C., Changeaux J.-P. Allosteric modulations of the nicotinic acetylcholine receptor. Trends Neurosci. 16:1993;181-186.
32. Lena C., Changeax J.-P. The role of β2-subunit-containing nicotinic acetylcholine receptors in the brain explored with a mutant mouse. Ann. NY Acad. Sci. 868:1999;611-616.
33. Lin N.-H., Gunn D.E., Li Y., He Y., Bai H., Ryther K.B., Kuntzweiler T., Donnelly-Roberts D.L., Anderson D.J., Campbell J.E., Sullivan J.P., Arneric S.P., Holladay M.W. Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist. Bioorg. Med. Chem. Lett. 8:1998;249-254.
34. 3H ]-nicotine to a single class of high affinity sites in rat brain membranes Mol. Pharmacol. 29:1986;448-454.
35. 3H ]nicotine binding to putative high affinity receptor sites in rat brain Mol. Pharmacol. 31:1987;392-400.
36. Lu Y., Grady S., Marks M.J., Picciotto M., Changeux J.-P., Collins A.C. Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes. J. Pharmacol. Exp. Ther. 287:1998;648-657.
37. Malpass J.R., Cox C.D. Synthesis of 5- and 6-chloropyridyl-substituted 2-azabicyclo[2.2.1]heptanes; novel epibatidine isomers. Tetrahedron Lett. 40:1999;1419-1422.
38. Marubio L.M., del Mar Arroyo-Jimenez M., Cordero-Erausquin M., Lena C., Le Novere N., de Kerchove d'Exaerde A., Huchet M., Damaj M.I., Changeux J.-P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature (London). 398:1999;305-810.
39. Nordberg A. Human nicotinic receptors - their role in aging and dementia. Neurochem. Int. 25:1994;93-97.
40. 3H ]Cytisine binding to nicotinic cholinergic receptors in brain Mol. Pharmacol. 39:1990;9-12.
41. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, lewy body dementia and alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
42. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., Fuxe K., Changeux J.-P. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature (London). 391:1998;173-177.
43. Picciotto M.R., Zoll M., Lena C., Bessis A., Lallemand Y., LeNovere N., Vincent P., Pich E.M., Brulet P., Changeux J.-P. Abnormal avoidance leaning in mice lacking functional high-affinity nicotine receptor in the brain. Nature (London). 374:1995;65-67.
44. Schmitt, J.D., Sharples, C.G.V., Caldwell, W.S., 1998. Aromatic-cation interactions in nicotinic acetylcholine receptor ligand binding. In Book of Abstracts, 216th ACS National Meeting, Boston, American Chemical Society, Washington, DC, MEDI-153.
45. Sheridan R.P., Nilakantan R., Dixon J.S., Venkataraghavan R. The ensemble approach to distance geometry: application to the nicotinic pharmacophore. J. Med. Chem. 29:1986;899-906.
46. Sussman J.L., Harel M., Frolow F., Oefner C., Goldman A., Toker L., Silman I. Atomic structure of acetylcholinesterase from torpedo california: a prototypic acetylcholine-binding protein. Science. 253:1991;872-879.
47. Tani Y., Saito K., Imoto M., Ohno T. Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain - an in vivo microdialysis study. Eur. J. Pharmacol. 351:1998;181-188.
48. Wasicak, J.T., Garvey, D.S., Holladay, M.W., Lin, N.-H., Ryther, K.B., 1998. Preparation of 7a-heteroarylhexahydro-1H-pyrrolizines as cholinergic synaptic transmission modulators. US 5733912.
49. Williams M., Arneric S. Beyond the tobacco debate: dissecting out the therapeutic potential of nicotine. Expert Opin. Invest. Drugs. 5:1996;1035-1045.
50. Wonnacott S., Soliakov L., Wilkie G., Redfern P., Marshall D. Presynaptic nicotinic acetycholine receptors in the brain. Drug Dev. Res. 38:1996;149-159.
51. 3H ]-cytisine with high affinity for binding to rat brain cortical membrane preparations. In: Clarke, P.B.S., Quik, M., Thurau, K., Adlkofer, F., (Eds.), International Symposium on Nicotine: The Effects of Nicotine on Biological Systems II Montreal, P32.
52. Zhang C., Trudell M.L. A short and efficient total synthesis of (±)-epibatidine. J. Org. Chem. 61:1996;7189-7191.
53. Zhong W., Gallivan J.P., Zhang Y., Li L., Lester H.A., Dougherty D.A. From ab initio quantum mechanics to molecular neurobiology: a cation-π binding site in the nicotinic receptor. Proc. Natl. Acad. Sci. U.S.A. 95:1998;12088-12093.
54. Zoli M., Lena C., Picciotto M.R., Changeux J.-P. Identification of four classes of brain nicotinic receptors using β2 mutant mice. J. Neurosci. 18:1998;4461-4472.
55. Zoli M., Picciotto M.R., Ferrari R., Cocchi D., Changeux J.-P. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J. 18:1999;1235-1244.